Apollomics, Inc. (APLM) vs MiNK Therapeutics, Inc. (INKT)

A side-by-side comparison of Apollomics, Inc. and MiNK Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Apollomics, Inc. logo
APLM
Apollomics, Inc.
$51M
$23.40HealthcareDelayed quote: Oct 6, 2026, 11:29 AM EDT
MiNK Therapeutics, Inc. logo
INKT
MiNK Therapeutics, Inc.
$58M
$11.71HealthcareDelayed quote: Oct 6, 2026, 11:29 AM EDT

Total return — APLM vs INKT

growth of $100 · dividends reinvested · last 5y
APLM -97.6% (-52.8%/yr)INKT -93.5% (-42.1%/yr)INKT compounded faster over this window
0100200300Start $10020222023202420252026$2$7
APLM INKT

APLM vs INKT: by the numbers

  • •INKT is the larger company ($58M vs $51M market cap).
  • •Both run net losses; INKT's is the smaller (0.00% vs -128.69% net margin).

Metrics side by side

Profitability

MetricAPLMINKT
Gross margin97.00%0.00%
Operating margin-111.45%0.00%
Net margin-128.69%0.00%
ROIC-2441.49%-604.20%

Growth (annualized)

MetricAPLMINKT
Revenue CAGR (5Y)35.84%N/A

Go deeper

Full APLM analysisFull INKT analysisInteractive comparison tool

Dig into the metrics

Apollomics ROEMiNK Therapeutics ROEApollomics operating marginMiNK Therapeutics operating marginApollomics revenue growthMiNK Therapeutics revenue growthApollomics free cash flowMiNK Therapeutics free cash flow

Apollomics & MiNK Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.